Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Day One Biopharmaceuticals, Inc. - Common Stock
(NQ:
DAWN
)
8.340
+0.030 (+0.36%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 4, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Day One Biopharmaceuticals, Inc. - Common Stock
< Previous
1
2
Next >
Day One Announces Three Year Follow-Up Data From OJEMDA™ (tovorafenib) Phase 2 FIREFLY-1 Trial at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting
November 24, 2025
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One to Participate in the Piper Sandler 37th Annual Healthcare Conference
November 18, 2025
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One to Acquire Mersana Therapeutics to Advance Mission to Bring New Medicines to People of All Ages with Life-Threatening Diseases
November 13, 2025
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One Announces New OJEMDA™ (tovorafenib) Data to be Presented in Oral Session at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting
November 10, 2025
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One Reports Third Quarter 2025 Financial Results and Corporate Progress
November 04, 2025
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One to Report Third Quarter 2025 Financial Results Tuesday, November 4, 2025
October 21, 2025
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One Reports Second Quarter 2025 Financial Results and Corporate Progress
August 05, 2025
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One to Report Second Quarter 2025 Financial Results Tuesday, August 5, 2025
July 22, 2025
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development
June 10, 2025
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One Reports First Quarter 2025 Financial Results and Corporate Progress
May 06, 2025
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025
April 22, 2025
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress
February 25, 2025
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025
February 11, 2025
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Biotech Investing: How PRV’s Can Unlock Major Opportunities (OSTX, DAWN, SWTX, PTCT)
February 05, 2025
Via
AB Newswire
Day One Reports Preliminary 2024 OJEMDA™ Net Product Revenue and Highlights 2025 Corporate Priorities
January 13, 2025
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 17, 2024
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development
November 20, 2024
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference
November 18, 2024
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One Reports Third Quarter 2024 Financial Results and Corporate Progress
October 30, 2024
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024
October 16, 2024
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One Reports Second Quarter 2024 Financial Results and Corporate Progress
July 30, 2024
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One Announces Oversubscribed $175.0 Million Private Placement
July 30, 2024
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers
June 18, 2024
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One Announces Sale of Priority Review Voucher for $108 Million
May 30, 2024
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One Reports First Quarter 2024 Financial Results and Corporate Progress
May 06, 2024
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
April 23, 2024
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress
February 26, 2024
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One Announces Two New Appointments to Board of Directors
January 17, 2024
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 19, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine
November 17, 2023
Data subsets to be shared today in plenary oral presentations at the 2023 Society for Neuro-Oncology Annual Meeting
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
